Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden

Annals of the Rheumatic Diseases

Volumn 75, Issue 7, 2016, Pages 1272-1278

  Wadström, Hjalmar ^a   Frisell, Thomas ^a   Sparén, Pär ^a   Askling, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADENOCARCINOMA IN SITU; ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CERVIX ADENOCARCINOMA; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MARRIAGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SWEDEN; TREATMENT INDICATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMPLICATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84956624040     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208263     Document Type: Article

References (31)

1. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-31.
2. Krynitz B, Edgren G, Lindelof B, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008-a Swedish population-based study. Int J Cancer 2013;132:1429-38.
3. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007;370:59-67.
4. Jin Y. Association of single nucleotide polymorphisms in tumor necrosis factor-alpha with cervical cancer susceptibility. Cell Biochem Biophys 2015;71:77-84.
5. Che H, Lukas C, Morel J, et al. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine 2014;81:215-21.
6. Mercer LK, Low AS, Galloway JB, et al. Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Ann Rheum Dis 2013;72:143-4.
7. Cordtz R, Mellemkjær L, Glintborg B, et al. Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with arthritis. Ann Rheum Dis 2015;74:1479-80.
8. Kim SC, Glynn RJ, Giovannucci E, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: A population-based cohort study. Ann Rheum Dis 2015;74:1360-7.
9. Parikh-Patel A, White RH, Allen M, et al. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 2009;20:1001-10.
10. Chen YJ, Chang YT, Wang CB, et al. The risk of cancer in patients with rheumatoid arthritis: A nationwide cohort study in Taiwan. Arthritis Rheum 2011;63:352-8.
11. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.
12. Azerkan F, Sparén P, Sandin S, et al. Cervical screening participation and risk among Swedish-born and immigrant women in Sweden. Int J Cancer 2012;130:937-47.
13. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12.
14. Neovius M, Simard J, Sundström A, et al. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. Ann Rheum Dis 2011;70:516-19.
15. Wadström H, Eriksson J, Neovius M, et al., ARTIS Study Group. How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)?. Scand J Rheumatol 2015;44:22-8.
16. Waldenlind K, Eriksson J, Grewin B, et al. Validation of the rheumatoid arthritis diagnosis in the Swedish National patient register: A cohort study from Stockholm County. BMC Musculoskelet Disord 2014;15:432.
17. Knight A, Sandin S, Askling J. Increased risk of autoimmune disease in families with Wegener's Granulomatosis. J Rheumatol 2010;37:2553-8.
18. Baecklund E, Ekbom A, Sparén P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317: 180-1.
19. Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register-a sample survey for year 1998. Acta Oncol 2009;48:27-33.
20. Pecorelli S, Benedet JL, Creasman WT, et al. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynecol Obstet 1999;64:5-10.
21. Kim SC, Schneeweiss S, Myers JA, et al. No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. Arthritis Rheum 2012;64:3076-82.
22. Kremers HM, Bidaut-Russell M, Scott CG, et al. Preventive medical services among patients with rheumatoid arthritis. J Rheumatoly 2003;30:1940-7.
23. Kiefe C, Funkhouser E, Fouad M, et al. Chronic disease as a barrier to breast and cervical cancer screening. J Gen Intern Med 1998;13:357-65.
24. MacLean CH, Louie R, Leake B, et al. QUality of care for patients with rheumatoid arthritis. JAMA 2000;284:984-92.
25. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
26. Carmona L, Abasolo L, Descalzo MA, et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 2011;41:71-80.
27. Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11-22.
28. Andrae B, Kemetli L, Sparén P, et al. Screening-preventable cervical cancer risks: Evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008;100:622-9.
29. Appleby P, Beral V, Berrington de González A, et al., International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13, 541 women with carcinoma of the cervix and 23, 017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006;118:1481-95.
30. Kjellberg L, Hallmans G, Ahren AM, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000;82:1332-8.
31. Saevarsdottir S, Wedrén S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011;63:26-36.